gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 22-I-036

## You asked:

Could you please tell me how many patients were treated in August 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibingo) 0
- Baricitinib (Olumiant) 23
- Bimekizumab (Bimzelx) <5
- Brodalumab (Kyntheum) 12
- Dupilumab (Dupixent) 61
- Ixekizumab (Taltz) 27
- Risankizumab (Skyrizi) 32
- Guselkumab (Tremfya) 30
- Secukinumab (Cosentyx) 30
- Tildrakizumab (Ilumetri) 24
- Tralokinumab (Adtralza) <5
- Upadacitinib (Rinvog) <5</li>
- Ustekinumab (Stelara) 75

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

